e-learning
resources
Milan 2017
Wednesday, 13.09.2017
Idiopathic pulmonary fibrosis: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice
K. Babu (Portsmouth, United Kingdom)
Source:
International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Session:
Idiopathic pulmonary fibrosis: from the bench to the bedside
Session type:
Poster Discussion
Number:
4879
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Babu (Portsmouth, United Kingdom). Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice. 4879
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Efficacy and safety of nintedanib in the elderly patient with IPF
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018
Year: 2018
Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Recent clinical treatment trials in IPF that focus on pirfenidone and nintedanib
Source: International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century"
Year: 2014
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Concomitant medications and efficacy of nintedanib in patients with IPF
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Efficacy and safety of omalizumab in real-life practice in India
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Efficacy and safety of Mepolizumab in a real world severe asthma cohort.
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Efficacy and tolerability of ciclesonide (CIC) in the treatment of 24,037 asthmatic patients in routine clinical care
Source: Annual Congress 2010 - Pharmacological treatment in primary care
Year: 2010
A real life multicenter national study on the use of nintedanib in moderate to severe IPF patients
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006
Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Real-life efficacy of Pirfenidone in a cohort of patients with IPF in Northern Greece
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials
Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept